Inspire Medical Systems Inc
F:2DR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Inspire Medical Systems Inc
F:2DR
|
US |
Inspire Medical Systems Inc
Inspire Medical Systems makes an implantable device that treats obstructive sleep apnea, a condition where the airway repeatedly closes during sleep. Its system works like a small pacemaker for breathing: a surgeon implants it under the skin, and it sends mild stimulation to a nerve that helps keep the airway open at night. The company’s main product is this therapy system, along with the tools and support needed to implant and use it. Its customers are mostly hospitals, sleep surgeons, and ear, nose, and throat specialists who select and implant the device for patients who have not done well with standard sleep apnea treatments such as CPAP. Inspire makes money by selling the device system and related components through the medical device supply chain, usually tied to the implantation procedure. In practice, the company sits between the doctor who diagnoses sleep apnea and the hospital or surgery center that performs the implant. What makes the business different is that it is not a broad sleep-apnea supplier or a disposable-device maker. It is focused on one specific treatment option for one specific patient group: people with moderate to severe obstructive sleep apnea who need an implanted alternative to masks and machines. That narrow focus gives it a clear role in sleep medicine and makes its business depend on physician adoption, patient selection, and reimbursement for an implanted therapy.
Inspire Medical Systems makes an implantable device that treats obstructive sleep apnea, a condition where the airway repeatedly closes during sleep. Its system works like a small pacemaker for breathing: a surgeon implants it under the skin, and it sends mild stimulation to a nerve that helps keep the airway open at night. The company’s main product is this therapy system, along with the tools and support needed to implant and use it.
Its customers are mostly hospitals, sleep surgeons, and ear, nose, and throat specialists who select and implant the device for patients who have not done well with standard sleep apnea treatments such as CPAP. Inspire makes money by selling the device system and related components through the medical device supply chain, usually tied to the implantation procedure. In practice, the company sits between the doctor who diagnoses sleep apnea and the hospital or surgery center that performs the implant.
What makes the business different is that it is not a broad sleep-apnea supplier or a disposable-device maker. It is focused on one specific treatment option for one specific patient group: people with moderate to severe obstructive sleep apnea who need an implanted alternative to masks and machines. That narrow focus gives it a clear role in sleep medicine and makes its business depend on physician adoption, patient selection, and reimbursement for an implanted therapy.
Beat and raise: Inspire said Q2 results came in ahead of expectations, helped by cost discipline and better-than-expected profitability, and it raised full-year 2026 guidance for revenue, adjusted operating margin, and adjusted EPS.
Revenue pressure: Q2 revenue fell 7.6% to $200.6 million, mainly because coding and reimbursement disruption continued to slow procedures and prior authorizations earlier in the year.
Project Horizon: The company launched a strategic growth plan to free up $30 million of annualized investment capacity, with most of the reinvestment aimed at patient flow, education, access, and support tools.
Reimbursement progress: Management said billing confusion is being managed, C codes are now in place, and hospital/ASC reimbursement rates remain unchanged; CMS also proposed higher 2027 facility rates, though final rules are due in November.
Clinical story: Inspire highlighted new data on Inspire V, cardiovascular risk markers, and a publication showing that BMI and neck circumference may help screen some patients without DISE.
2027 setup: Management was cautious on formal 2027 guidance, but said coding clarity, reimbursement progress, Project Horizon, and new clinical evidence could support a re-acceleration next year.
